Cue Biopharma Files 8-K on Director/Officer Changes
Ticker: CUE · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1645460
Sentiment: neutral
Topics: leadership-change, governance, officer-appointment
TL;DR
Cue Biopharma updated its board and execs on 6/5. Big changes coming?
AI Summary
On June 5, 2024, Cue Biopharma, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information on the election of new directors and the appointment of certain officers, as well as details regarding compensatory arrangements for these individuals. The company also reported on matters submitted to a vote of its security holders.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, governance, or operational focus, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and executive compensation can introduce uncertainty and potential shifts in company strategy.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- June 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 40 Guest Street Boston, Massachusetts 02135 (address) — Principal Executive Offices
- Imagen Biopharma, Inc. (company) — Former Company Name
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but specific names and details of the changes are not provided in the provided text.
Who were the newly appointed officers?
The filing mentions the appointment of certain officers but does not list their names or specific roles in the provided text.
What are the details of the compensatory arrangements for the new officers and directors?
The filing states that information on compensatory arrangements is included, but the specific details are not present in the provided text.
What matters were submitted to a vote of security holders?
The filing notes that matters were submitted to a vote of security holders, but the nature of these matters is not specified in the provided text.
When was the former company name, Imagen Biopharma, Inc., changed?
The date of the name change from Imagen Biopharma, Inc. to Cue Biopharma, Inc. was June 17, 2015.
Filing Stats: 889 words · 4 min read · ~3 pages · Grade level 11.3 · Accepted 2024-06-07 16:00:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
Filing Documents
- cue-20240605.htm (8-K) — 78KB
- 0000950170-24-070566.txt ( ) — 214KB
- cue-20240605.xsd (EX-101.SCH) — 44KB
- cue-20240605_htm.xml (XML) — 4KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on June 5, 2024. The certified results of the matters voted upon at the Annual Meeting, which are more fully described in the Company's Proxy Statement for the Annual Meeting as filed with the SEC on April 26, 2024, are as follows (where applicable, voting results reflect fractional shares rounded down to the nearest whole share): 1. The Company's stockholders elected the following nominees to the Company's Board to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows: For Withheld Broker Non-Votes Daniel R. Passeri 13,099,740 765,119 20,311,373 Frank Morich 7,990,004 5,605,204 20,581,024 Frederick Driscoll 12,486,167 1,378,692 20,311,373 Pamela Garzone 13,169,810 695,049 20,311,373 Peter A. Kiener 9,038,525 4,822,811 20,314,896 Patrick Verheyen 13,138,525 726,334 20,311,373 2. The Company's stockholders ratified the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, with votes cast as follows: For Against Abstain 32,418,349 1,635,231 122,652 3. The Company's stockholders approved a non-binding advisory proposal on the compensation of the Company's named executive officers, with votes cast as follows: For Against Abstain Broker Non-Votes 11,745,009 1,924,707 195,143 20,311,373
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: June 7, 2024 By: /s/ Daniel R. Passeri Name: Daniel R. Passeri Title: Chief Executive Officer